Ellis S - Search Results

1

The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor.

Pollack S, Young L, Bilsland J, Wilkie N, Ellis S, Hefti F, Broughton H, Harper S. Pollack S, et al. Among authors: ellis s. Mol Pharmacol. 1999 Jul;56(1):185-95. doi: 10.1124/mol.56.1.185. Mol Pharmacol. 1999. PMID: 10385700

2

The non-peptidyl fungal metabolite L-783,281 activates TRK neurotrophin receptors.

Wilkie N, Wingrove PB, Bilsland JG, Young L, Harper SJ, Hefti F, Ellis S, Pollack SJ. Wilkie N, et al. Among authors: ellis s. J Neurochem. 2001 Sep;78(5):1135-45. doi: 10.1046/j.1471-4159.2001.00504.x. J Neurochem. 2001. PMID: 11553687 Free article.

3

Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.

Fricker M, Lograsso P, Ellis S, Wilkie N, Hunt P, Pollack SJ. Fricker M, et al. Among authors: ellis s. Arch Biochem Biophys. 2005 Jun 15;438(2):195-205. doi: 10.1016/j.abb.2005.04.013. Arch Biochem Biophys. 2005. PMID: 15907786

4

The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.

Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque PA, Boussiquet-Leroux C, Churcher I, Atack JR, Harrison T, Shearman MS. Best JD, et al. Among authors: ellis s. J Pharmacol Exp Ther. 2007 Feb;320(2):552-8. doi: 10.1124/jpet.106.114330. Epub 2006 Nov 10. J Pharmacol Exp Ther. 2007. PMID: 17099072

5

Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].

Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, Shearman MS, Williamson TL, Atack JR. Best JD, et al. Among authors: ellis s. J Pharmacol Exp Ther. 2005 May;313(2):902-8. doi: 10.1124/jpet.104.081174. Epub 2005 Mar 2. J Pharmacol Exp Ther. 2005. PMID: 15743924

6

Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes.

Clarke EE, Churcher I, Ellis S, Wrigley JD, Lewis HD, Harrison T, Shearman MS, Beher D. Clarke EE, et al. Among authors: ellis s. J Biol Chem. 2006 Oct 20;281(42):31279-89. doi: 10.1074/jbc.M605051200. Epub 2006 Aug 9. J Biol Chem. 2006. PMID: 16899457 Free article.

7

Functional overexpression of gamma-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activity.

Wrigley JD, Schurov I, Nunn EJ, Martin AC, Clarke EE, Ellis S, Bonnert TP, Shearman MS, Beher D. Wrigley JD, et al. Among authors: ellis s. J Biol Chem. 2005 Apr 1;280(13):12523-35. doi: 10.1074/jbc.M413086200. Epub 2004 Dec 21. J Biol Chem. 2005. PMID: 15613471 Free article.

8

Pulmonary veno-occlusive disease: A systematic review of risk factors, clinical presentation, diagnostic investigations, treatment outcomes and prognostic factors.

Thong LP, Hakak-Zargar B, Burns AT, Harisis GN, Ellis SJ, Ha FJ. Thong LP, et al. Among authors: ellis sj. J Med Imaging Radiat Oncol. 2024 Dec 11. doi: 10.1111/1754-9485.13814. Online ahead of print. J Med Imaging Radiat Oncol. 2024. PMID: 39661909

9

Structural complexity of glyphosate and aminomethylphosphonate metal complexes.

Rusli O, Lloyd Williams OH, Chakraborty P, Neumaier M, Hennrich F, Bakels S, Hes K, Rijs AM, Ucur B, Ellis SR, Pachulicz RJ, Pukala TL, Rijs NJ. Rusli O, et al. Among authors: ellis sr. Phys Chem Chem Phys. 2024 Dec 10. doi: 10.1039/d4cp04019h. Online ahead of print. Phys Chem Chem Phys. 2024. PMID: 39655719

10

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.

TREATT Trial Investigators. TREATT Trial Investigators. Lancet Haematol. 2024 Dec 3:S2352-3026(24)00317-X. doi: 10.1016/S2352-3026(24)00317-X. Online ahead of print. Lancet Haematol. 2024. PMID: 39642900

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,921 results

Search Page

Filters